1 – 49 of 49
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Next-generation CD40 agonists for cancer immunotherapy
(
- Contribution to journal › Scientific review
-
Mark
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1) : a single-arm, multicentre phase 1b/2 study
(
- Contribution to journal › Article
-
Mark
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes
(
- Contribution to journal › Article
- 2023
-
Mark
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
(
- Contribution to journal › Article
-
Mark
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
(
- Contribution to journal › Article
-
Mark
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
(
- Contribution to journal › Article
- 2022
-
Mark
Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
(
- Contribution to journal › Article
- 2021
-
Mark
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
(
- Contribution to journal › Article
-
Mark
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
(
- Contribution to journal › Article
-
Mark
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer.
2020) The Society for Immunotherapy of Cancer's (SITC) 35th annual meeting In Journal for ImmunoTherapy of Cancer 8(Suppl. 3).(
- Contribution to journal › Published meeting abstract
- 2018
-
Mark
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
(
- Contribution to journal › Article
- 2017
-
Mark
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
(
- Contribution to journal › Article
-
Mark
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
(
- Contribution to journal › Article
- 2016
-
Mark
Selective FcγR engagement by human agonistic anti-CD40 antibodies
(
- Contribution to journal › Debate/Note/Editorial
- 2015
-
Mark
Kick-starting the cancer-immunity cycle by targeting CD40
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
(
- Contribution to journal › Article
-
Mark
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
(
- Contribution to journal › Article
- 2009
-
Mark
Attovial-based antibody nanoarrays.
(
- Contribution to journal › Article
- 2008
-
Mark
Detection of pancreatic cancer using antibody microarray-based serum protein profiling
(
- Contribution to journal › Article
-
Mark
Sensitivity of HIV-1 primary isolates to human anti-CD40 antibody-mediated suppression is related to co-receptor use
(
- Contribution to journal › Article
-
Mark
Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.
(
- Contribution to journal › Article
-
Mark
The Applicability of a Cluster of Differentiation Monoclonal Antibody Microarray to the Diagnosis of Human Disease
(
- Contribution to journal › Article
-
Mark
Phenotypic protein profiling of different B cell sub-populations using antibody CD-microarrays
(
- Contribution to journal › Article
-
Mark
Identification of a strongly activating human anti-CD40 antibody that suppresses HIV-1 infection
(
- Contribution to journal › Article
-
Mark
Multiplexed Lipid Dip-Pen Nanolithography on Subcellular Scales for the Templating of Functional Proteins and Cell Culture
(
- Contribution to journal › Article
- 2007
-
Mark
Development of atto-vial based antibody arrays
2007) Micro-and Nano-Engineering(
- Contribution to conference › Abstract
-
Mark
Recombinant antibdy microarray based oncoproteomics detects cancer and defines a predictor of survival for pancreatic carcinoma
(
- Contribution to journal › Published meeting abstract
-
Mark
Antibody microarray based oncoproteomics - analysis of breast cancer proteomes
(
- Contribution to journal › Published meeting abstract
-
Mark
Developmentof atto-vial based antibody arrays
2007) Nano2life(
- Contribution to conference › Abstract
-
Mark
Developmentof atto-vial based antibody arrays
2007) Nanobiotech Europe(
- Contribution to conference › Abstract
-
Mark
Serum protein profiling of metastatic breast cancer
(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
The application of CD antigen proteomics to pharmacogenomics
(
- Contribution to journal › Scientific review
-
Mark
Multiplex detection of surface molecules on colorectal cancers
(
- Contribution to journal › Article
-
Mark
Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays
(
- Contribution to journal › Article
-
Mark
High-throughput membrane proteomics using recombinant antibody microarrays
(
- Contribution to journal › Published meeting abstract
-
Mark
Antibody microarray based oncoproteomics - analysis of breast cancer proteomes
2006) 29th annual San Antonio breast cancer symposium In Proceedings of the 29th annual San Antonio breast cancer symposium(
- Contribution to journal › Published meeting abstract
-
Mark
Protein expression profiling using recombinant antibody microarrays
2006) 5th annual HUPO world congress, 2006(
- Contribution to conference › Abstract
-
Mark
Protein expression profiling in normal and malignant stomach tissue using recombinant antibody microarrays
2006) PEPTALK(
- Contribution to conference › Abstract
- 2005
-
Mark
Protein expression profiling in normal and malignant stomach tissue using recombinant antibody microarrays
2005) Advances in Microarray Technology, 2005(
- Contribution to conference › Abstract
- 2004
-
Mark
A novel mammalian display system for the selection of protein-protein interactions by decoy receptor engagement
(
- Contribution to journal › Article
-
Mark
Profiling of internalizing tumor-associated antigens on breast and pancreatic cancer cells by reversed genomics
(
- Contribution to journal › Article
- 2003
-
Mark
Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti-immunoglobulin M-induced apoptosis
(
- Contribution to journal › Article
-
Mark
Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of naïve B-cells from anti-IgM induced apoptosis
2003) p.01-14(
- Contribution to conference › Paper, not in proceeding
-
Mark
Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies
(
- Contribution to journal › Article
- 2002
-
Mark
Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library
(
- Contribution to journal › Article
-
Mark
In vitro molecular evolution of antibody genes mimicking receptor revision
(
- Contribution to journal › Article
-
Mark
The CD40 Receptor - Target,Tool and Technology
2002)(
- Thesis › Doctoral thesis (compilation)